Arrow Generics, a Watson Company, launches Candesartan Tablets upon patent expiry
Posted on 29th Apr 2012
Arrow Generics, a Watson Company are very proud to announce the launch of Candesartan Tablets on day 1 of patent expiry. Candesartan is available in strengths of 2mg, 4mg, 8mg, 16mg and 32mg.
Candesartan is the generic version of Takeda’s Amias® and is indicated for the:
Treatment of essential hypertension in adults.
Treatment of adult patients with heart failure and impaired left ventricle systolic function (left ventricular ejection fraction ≤ 40%) as add-on therapy to Angiotensin Converting Enzyme (ACE) inhibitors or when ACE inhibitors are not tolerated.
The addition of Candesartan tablets to the Arrow portfolio once again demonstrates Arrow’s commitment to develop and bring to market patent expiring molecules on day 1.
If you require further information please contact us via the web page.
